Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products.

Many cyclic peptide natural products are larger and structurally more complex than conventional small molecule drugs. Although some molecules in this class are known to possess favorable pharmacokinetic properties, there have been few reports on the membrane permeabilities of cyclic peptide natural products. Here, we present the passive membrane permeabilities of 39 cyclic peptide natural products, and interpret the results using a computational permeability prediction algorithm based on their known or calculated 3D conformations. We found that the permeabilities of these compounds, measured in a parallel artificial membrane permeability assay, spanned a wide range and demonstrated the important influence of conformation on membrane permeability. These results will aid in the development of these compounds as a viable drug paradigm.

[1]  J. Jeffery.  Cyclosporine analogues. , 1991, Clinical biochemistry.

[2]  Masataka Harada,et al.  Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. , 2003, Journal of medicinal chemistry.

[3]  Matthew P Jacobson,et al.  Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.

[4]  Matthew P. Jacobson,et al.  Predicting and improving the membrane permeability of peptidic small molecules. , 2012, Journal of medicinal chemistry.

[5]  D. Seebach,et al.  Complexation and medium effects on the conformation of cyclosporin A studied by NMR spectroscopy and molecular dynamics calculations. , 1990, Biochemical pharmacology.

[6]  H. Kessler,et al.  N-methylated cyclic pentaalanine peptides as template structures. , 2006, Journal of the American Chemical Society.

[7]  T. Katoh,et al.  Selection-based discovery of druglike macrocyclic peptides. , 2014, Annual review of biochemistry.

[8]  Fabrizio Giordanetto,et al.  Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. , 2014, Chemistry & biology.

[9]  Ronald W. Barrett,et al.  Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.

[10]  A. Burgess,et al.  Modeling conformational changes in cyclosporin A , 1995, Protein science : a publication of the Protein Society.

[11]  Ian Collins,et al.  Macrocycles in new drug discovery. , 2012, Future medicinal chemistry.

[12]  H. Kessler,et al.  The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. , 2011, Molecular pharmaceutics.

[13]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[14]  T. Renné,et al.  Factor XII: a drug target for safe interference with thrombosis and inflammation. , 2014, Drug discovery today.

[15]  Fabrizio Giordanetto,et al.  Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.

[16]  Joshua A. Kritzer,et al.  Peptide Bicycles that Inhibit the Grb2 SH2 Domain , 2012, Chembiochem : a European journal of chemical biology.

[17]  Michael M. Madden,et al.  Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition. , 2011, Bioorganic & medicinal chemistry letters.

[18]  H. Loosli,et al.  [Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with a remarkable immunosuppressive activity]. , 1976, Helvetica chimica acta.

[19]  Armin Widmer,et al.  Peptide conformations. Part 31. The conformation of cyclosporin a in the crystal and in solution , 1985 .

[20]  R. Lokey,et al.  Form and function in cyclic peptide natural products: a pharmacokinetic perspective. , 2013, Current topics in medicinal chemistry.

[21]  Dima Kozakov,et al.  How Proteins Bind Macrocycles , 2014, Nature chemical biology.

[22]  Siegfried S. F. Leung,et al.  Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. , 2015, Journal of the American Chemical Society.

[23]  T. Shimada,et al.  Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine. , 2005, Drug metabolism and pharmacokinetics.

[24]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[25]  D. Chan,et al.  Analysis of the Human Endogenous Coregulator Complexome , 2011, Cell.

[26]  H. Suga,et al.  Flexizyme-mediated genetic reprogramming as a tool for noncanonical peptide synthesis and drug discovery. , 2013, Chemistry.

[27]  T. Kodadek,et al.  Investigation of the relative cellular permeability of DNA-binding pyrrole-imidazole polyamides. , 2009, Journal of medicinal chemistry.

[28]  Janice M Reichert,et al.  The future of antibodies as cancer drugs. , 2012, Drug discovery today.

[29]  Joshua A. Kritzer,et al.  Comprehensive Analysis of Loops at Protein-Protein Interfaces for Macrocycle Design , 2014, Nature chemical biology.

[30]  S. McCleary,et al.  Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. , 2001, Journal of medicinal chemistry.

[31]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2009, Nature.

[32]  Shaomeng Wang,et al.  Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. , 2012, Journal of medicinal chemistry.

[33]  H. Kessler,et al.  N‐Methylation of Peptides: A New Perspective in Medicinal Chemistry , 2009 .

[34]  G. Sheldrick,et al.  Crystal Structure and Packing of Isocyclosporin A , 1996 .

[35]  Spiros Liras,et al.  Improving on nature: making a cyclic heptapeptide orally bioavailable. , 2014, Angewandte Chemie.

[36]  Siegfried S. F. Leung,et al.  Testing Physical Models of Passive Membrane Permeation , 2012, J. Chem. Inf. Model..

[37]  Cristiano Ruch Werneck Guimarães,et al.  Use of 3D Properties to Characterize Beyond Rule-of-5 Property Space for Passive Permeation , 2012, J. Chem. Inf. Model..

[38]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[39]  R. Oliyai,et al.  Kinetics of acid-catalyzed degradation of cyclosporin A and its analogs in aqueous solution. , 2009, International journal of peptide and protein research.

[40]  Yizhong Zhang,et al.  On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds , 2011, Nature chemical biology.

[41]  Yizhong Zhang,et al.  Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance(). , 2012, MedChemComm.

[42]  Matthew P Jacobson,et al.  Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. , 2015, Journal of medicinal chemistry.

[43]  H. Berendsen,et al.  Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations. , 1996, Biophysical journal.

[44]  C. Heinis,et al.  Drug discovery: tools and rules for macrocycles. , 2014, Nature chemical biology.

[45]  Cristina Rossi,et al.  hNK2 receptor antagonists. The use of intramolecular hydrogen bonding to increase solubility and membrane permeability. , 2011, Bioorganic & medicinal chemistry letters.

[46]  Stefan Berger,et al.  Spatial structure of cyclosporin A and insight into its flexibility , 2013 .

[47]  B. Chowdhry,et al.  Solution conformations of cyclosporins and magnesium‐cyclosporin complexes determined by vibrational circular dichroism , 2004, Biopolymers.

[48]  S. Yıldırım,et al.  Comparison of Neoral and Sandimmun for induction and maintenance immunosuppression after kidney transplantation , 1997, Transplant international : official journal of the European Society for Organ Transplantation.

[49]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[50]  Matthew P Jacobson,et al.  Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.

[51]  Hui Zhu,et al.  Unambiguous assignment of vibrational spectra of cyclosporins A and H. , 2010, The journal of physical chemistry. A.

[52]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[53]  S. Chiou,et al.  Study of structure-activity correlation in destruxins, a class of cyclodepsipeptides possessing suppressive effect on the generation of hepatitis B virus surface antigen in human hepatoma cells. , 1996, Biochemical and biophysical research communications.

[54]  David W. Colby,et al.  Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. , 2004, Proceedings of the National Academy of Sciences of the United States of America.